Clopidogrel bisulfate: In ST-segment elevation myocardial infarction

American Journal of Cardiovascular Drugs

Volumn 6, Issue 6, 2006, Pages 407-414

  Dickie, Jennifer S ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIMETIDINE; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; ESTROGEN; FIBRINOLYTIC AGENT; FLUINDOSTATIN; HEPARIN; NAPROXEN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PLACEBO; RETEPLASE; STREPTOKINASE; TAMOXIFEN; TENECTEPLASE; THEOPHYLLINE; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FIBRINOLYSIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEMORRHAGIC STROKE; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; SKIN DISEASE; ST SEGMENT ELEVATION; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; ULCER;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33846108688     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200606060-00008     Document Type: Article

References (21)

1. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000 Aug; 60 (2): 347-77
2. Easthope SE, Jarvis B. Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes. Am J Cardiovasc Drugs 2001; 1 (6): 467-74; discussion 475-6
3. Lyseng-Williamson KA, Plosker GL. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006; 24 (7): 709-26
4. American Heart Association. Heart disease and stroke statistics: 2006 update [online]. Available from URL: http://circ.ahajournals.org/cgi/reprint/ CIRCULATIONAHA.105.171600v1 [Accessed 2006 Sep 17]
5. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. Drug Saf 1999 Oct; 21 (4): 325-35
6. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16; 345 (7): 494-502
7. Sullivan, S. Clopidogrel adds further protection in STEMI. Inpharma 2005 Mar 26; (No. 1480/1481): 17-8
8. Cadroy Y, Harker LA. Platelets, thrombosis and antithrombotic therapies. Antonaccio MJ, editor. Cardiovascular Pharmacology. 3rd ed. New York: Raven Press, 1990: 515-39
9. Sanofi-Aventis. Plavix prescribing information. Bridgewater (NJ): Sanofi-Aventis, 2006
10. Pereillo J-M, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30 (11): 1288-95
11. Savi P, Pereillo J-M, Uzabiaga J, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6
12. Lins R, Broekhuysen J, Necciari J, et al. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 1999; 25 Suppl. 2: 29-33
13. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003 Jan; 31 (1): 53-9
14. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 Nov 5; 366 (9497): 1607-21
15. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24; 352 (12): 1179-89
16. Scirica BM, Sabatine MS, Morrow DA, et al. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 2006 Jul 4; 48 (1): 37-42
17. Gibson CM, Ly HQ, Murphy SA, et al. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol 2006 Sep 15; 98 (6): 761-3
18. Gibson CM, Kirtane AJ, Aroesty JM, et al. Clopidogrel is associated with improved angiographic measures in ST elevation myocardial infarction: a CLARITY-TIMI 28 substudy [abstract no. 2695]. Circulation 2005 Oct 25; 112 (Suppl. 17): 568
19. Montalescot G, Verheugt F, Sabatine MS, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation myocardial infarction: the Prehospital CLARITY-TIMI 28 substudy [abstract no. 2691]. Circulation 2005 Oct 25; 112 (Suppl. 17): 567
20. Zeymer U, Gitt AK, Junger C, et al. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006 Nov; 27 (22): 2661-6
21. European Commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack [media release]. Paris: Sanofi-Aventis, Bristol-Myers Squibb, 2006 Sep 7